NasdaqGS:TERNPharmaceuticals
What Terns Pharmaceuticals (TERN)'s Expanded Global Rights to TERN-701 Mean For Shareholders
Terns Pharmaceuticals previously announced an amendment to its Exclusive Option and License Agreement with Hansoh, converting a non-exclusive license into an exclusive, sublicensable, royalty-bearing, perpetual worldwide license for TERN-701 outside China, Taiwan, Hong Kong, and Macau.
This move materially increases Terns’ control over the global development and commercialization path of TERN-701, reshaping the asset’s long-term commercial potential.
Next, we’ll examine how gaining an...